CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
- Mechanism
- Curator reviewed
CNS 5161 is a selective and high affinity N-methyl-D-aspartate (NMDA) receptor antagonist with preferential binding to the activated form of the receptor. CNS 5161 also penetrates the brain well and can be used to label selectively brain NMDA receptors in vivo. A radioactive form of CNS 5161 may be used as an agent to monitor NMDA receptors in the human brain using Positron Emission Tomography ("PET") and "the significance of a selective, validated radiopharmaceutical agent suitable for detecting widespread as well as highly localized changes in the NMDA receptor in the living brain cannot be exaggerated".
- Primary indication
- Investigated for use/treatment in migraine and cluster headaches, neuropathy (diabetic), and pain (acute or chronic).Curator reviewed
- Formula / weight
- C16H18ClN3S2 · 351.917 g/mol (avg)
- Code names
- CNS-5161
Resolves to
JHVHEDNLONERHY-UHFFFAOYSA-NSMILESCSC1=CC(\N=C(/N)N(C)C2=CC(SC)=CC=C2)=C(Cl)C=C1What you can answer from here — as of April 02, 2025
Which drugs share a target with CNS-5161, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account